Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Prolocor logo — Advancing patient care by empowering physicians with effecti...

Prolocor

Advancing patient care by empowering physicians with effective precision diagnostics for cardiovascular disease.

Founded 2020 United States Philadelphia, United States 8 employees Convertible Note Total: $6.90M Biotechnology, Health Care

General Information

Company Name Prolocor
Founded Year 2020
Location United States Philadelphia, United States +2
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care
Funding Stage Convertible Note
Social

Get notified when Prolocor moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Prolocor

Prolocor is a biotechnology startup that aims to revolutionize patient care in cardiovascular disease. With a focus on precision diagnostics, Prolocor addresses the critical treatment decision-making process for the 50 million individuals living with chronic coronary artery disease in the U.S., Europe, and Japan. The company's innovative precision tool, led by a team deeply versed in thrombosis and cardiovascular disease, aims to guide treatment decisions by matching therapy intensity with the risk of events. Prolocor's groundbreaking strategy centers around platelet FcγRIIa and introduces a pioneering precision diagnostic test that quantifies FcγRIIa on the surface of platelets. Founded in 2020, the company secured a notable $1.70MConvertible Note investment on 27 February 2024 with the backing of Green Park & Golf Ventures and the LabCorp Venture Fund. Operating from the United States, Prolocor stands at the forefront of advancing the field of cardiovascular care with its innovative approach, poised for significant impact in the biotechnology and healthcare sectors.

Taxonomy: precision diagnostics, cardiovascular disease, chronic coronary artery disease, acute coronary syndrome, therapy decision-making, thrombosis, platelet FcγRIIa, commercialization strategy, precision diagnostic test, cardiovascular risk assessment, bleeding risk assessment, heart attack prevention, stroke prevention, cardiovascular death prevention

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 2
Investor
•••• •••• 		27 Feb 2024
Seed Round •••••• 2
Investor Investor
16 Aug 2022
Grant •••••• 1 •••• •••• 16 Aug 2022

Prolocor Alternatives & Competitors

Prolocor vs
GENinCode Predictive Genetics
GENinCode Predictive Genetics United Kingdom

Clinical Genetics and Precision Medicine. Safeguarding your future health.

Post Ipo Equity
47 employees
Biotechnology, Health Care
Prolocor vs
Artrya Ltd
Artrya Ltd Australia

We are changing the way Coronary Heart Disease is diagnosed and treated.

Series A
44 employees
AI, Biotechnology
Prolocor vs
DalCor Pharmaceuticals
DalCor Pharmaceuticals Canada

Pioneering Pharmacogenetic Precision Medicine for Cardiovascular Disease

Series D
19 employees
Biotechnology, Health Care

FAQ About Prolocor

Advancing patient care by empowering physicians with effective precision diagnostics for cardiovascular disease.
Prolocor was founded in 2020.
Prolocor is headquartered in Philadelphia, United States.
Prolocor operates in the following industries: Biotechnology, Health Care.
Prolocor has approximately 8 employees.
Prolocor has completed 3 funding rounds, raising a total of $6.90M. The latest funding stage is Convertible Note.
Top alternatives and competitors to Prolocor include GENinCode Predictive Genetics , Artrya Ltd, DalCor Pharmaceuticals, Soundbite Medical Solutions Inc., Cleveland HeartLab, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prolocor and GENinCode Predictive Genetics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Prolocor and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy